Quantcast

Latest Regulus Therapeutics Stories

2014-07-16 08:27:14

CARLSBAD, Calif., July 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTR(Rx) in patients with familial amyloid polyneuropathy (FAP). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO ISIS-TTR(Rx) is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare...

2014-06-25 08:30:45

- New Method of Use Claims Strengthen Patent Estate Covering microRNA-122 Inhibitors for the Treatment of HCV Infection - LA JOLLA, Calif., June 25, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that the U.S. Patent and Trademark Office ("USPTO") has granted a patent in the company's exclusively licensed 'Sarnow' patent estate, for claims related to...

2014-06-24 08:29:49

CARLSBAD, Calif., June 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTR(Rx) in patients with familial amyloid polyneuropathy (FAP). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO ISIS-TTR(Rx) is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and...

2014-06-16 08:28:15

- Recognized Industry Leader Brings Extensive Clinical and Product Development Expertise - LA JOLLA, Calif., June 16, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Paul C. Grint, M.D. to its executive management team as Chief Medical Officer. In his new role, Dr. Grint will be responsible for leading and expanding Regulus'...

2014-05-16 08:25:56

CARLSBAD, Calif., May 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' R&D Day Presentation When: Thursday, May 22 at 12:00 p.m. ET /9:00 a.m. PT Where: www.isispharm.com How: Live on the Internet. Simply log onto our website listed above. If you are unable to...

2014-05-09 16:24:39

LA JOLLA, Calif., May 9, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus, will present a company overview at the Bank of America Merrill Lynch 2014 Healthcare Conference on Thursday, May 15, 2014 at 12:00 p.m. PDT. The conference is being held at the Encore at the Wynn Las Vegas....

2014-05-08 16:27:14

- 'Clinical Map Initiative' On Track; Advanced RG-101 and RG-012, Expect to Nominate Third microRNA Clinical Candidate by YE 2014 - LA JOLLA, Calif., May 8, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results and highlights for the quarter ended March 31, 2014 and provided a summary of recent corporate highlights. "In the first quarter of...

2014-05-01 16:32:43

LA JOLLA, Calif., May 1, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended March 31, 2014 on Thursday, May 8, 2014, after the U.S. financial markets close. Regulus will host a conference call and webcast on Thursday, May 8, 2014, at 5:00 pm Eastern Daylight Time to discuss...

2014-04-30 16:30:42

LA JOLLA, Calif., April 30, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus, will present a company overview at the Deutsche Bank 39(th) Annual Healthcare Conference on Wednesday, May 7, 2014 at 8:40 a.m. EDT. The conference is being held at The...

2014-04-15 08:28:24

DUBLIN, Apr. 15, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/6zn3pr/global_microrna ) has announced the addition of the "Global MicroRNA Market Report" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The analysts forecast the Global MicroRNA market to grow at a CAGR of 17.51 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in microRNA research funding....


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related